Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 27;9(1):e00008-18. doi: 10.1128/mBio.00008-18

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Fernandez et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 1 — Neutralization activity of anti-JEV MAbs. (A) Serum samples from humans previously immunized against JEV with an inactivated virion vaccine were tested against a panel of JEV strains (2372/79 [GI], MAR 859 [GI], Bennett [GII], SA14 [GIII], SA14-14-2 [GIII], Nakayama [GIII], and JKT 7887 [GIV]) by focus-forming assay (FFA) for neutralization activity. Serial serum dilutions were incubated with 10² FFU for 1 h at 37°C, and Vero cells were subsequently infected and stained. (B) Neutralization curves of eight mouse anti-JEV MAbs (JEV-27, JEV-31, JEV-106, JEV-117, JEV-131, JEV-128, JEV-143, and JEV-169) against the indicated strains. (C) Neutralization curves of human-derived anti-JEV MAbs (hJEV-11, hJEV-69, hJEV-75, and hJEV-80) against the indicated strains. All data are representative of three independent experiments performed in triplicate.